A role for DICAM+ mononuclear phagocytes in controlling neuroinflammation in multiple sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40791582/
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). In MS, CNS-infiltrating monocytes differentiate to tissue resident macrophages which are found in large numbers within...
Study reveals DICAM⁺ mononuclear phagocytes suppress neuroinflammation in MS. Natalizumab-treated patients retain these cells with increased soluble DICAM, potentially mediating anti-inflammatory effects via cytokine modulation, supporting therapeutic relevance for Tysabri’s immune trafficking blockade.
Effect of Early Treatment Intensity on Progression Independent of Relapse Activity and Disability Accumulation in Multiple Sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40791714/
While HEET reduces risk of RAW, it does not significantly affect the risk of PIRA, even in patients diagnosed before age 30. It also does not significantly affect the risk...
Hypoxia in multiple sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40347693/
Low oxygen availability (hypoxia) is a prominent but poorly understood feature in multiple sclerosis (MS). Whether hypoxia causes or drives MS pathology and symptoms or whether it is a consequence...
Hypoxia influences multiple sclerosis pathology, with both oxygen supplementation and controlled hypoxia exposure showing therapeutic potential. Hypoxia conditioning and exercise may offer disease-modifying effects, though key questions remain.
Advancements in multiple sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40171883/
The global prevalence of multiple sclerosis (MS) is increasing, and early diagnosis and treatment is essential in mitigating disability. While recent therapeutic advancements have significantly reduced relapse rates, the progressive...
Multiple sclerosis prevalence is rising; updated diagnostics, emerging biomarkers, and innovative therapies—including CAR T-cell therapy and EBV vaccination—aim to enhance early intervention and address progressive disease challenges.
Italian MS specialists propose redefining MS as a continuum of inflammation and neurodegeneration, advocating for revised diagnostics, novel biomarkers, and therapies targeting smouldering disease beyond traditional relapsing and progressive classifications.